La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Palatin Technologies Gestione

Gestione criteri di controllo 3/4

Palatin Technologies' Il CEO è Carl Spana, nominato in Jun2000, e ha un mandato di 24.17 anni. la retribuzione annua totale è $ 1.30M, composta da 53.7% di stipendio e 46.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.35% delle azioni della società, per un valore di $ 371.27K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 13.7 anni e 19.1 anni.

Informazioni chiave

Carl Spana

Amministratore delegato

US$1.3m

Compenso totale

Percentuale dello stipendio del CEO	53.7%
Mandato del CEO	24.2yrs
Proprietà del CEO	1.3%
Durata media del management	13.7yrs
Durata media del Consiglio di amministrazione	19.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Carl Spana rispetto agli utili di Palatin Technologies?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	n/a	n/a	-US$35m
Dec 31 2023	n/a	n/a	-US$35m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	US$1m	US$700k	-US$28m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	n/a	n/a	-US$26m
Sep 30 2022	n/a	n/a	-US$37m
Jun 30 2022	US$1m	US$640k	-US$36m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	n/a	n/a	-US$35m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	US$2m	US$620k	-US$34m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	n/a	n/a	-US$27m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	US$2m	US$600k	-US$22m
Mar 31 2020	n/a	n/a	US$37m
Dec 31 2019	n/a	n/a	US$37m
Sep 30 2019	n/a	n/a	US$37m
Jun 30 2019	US$2m	US$505k	US$36m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	n/a	n/a	US$344k
Sep 30 2018	n/a	n/a	US$8m
Jun 30 2018	US$3m	US$491k	US$25m

Compensazione vs Mercato: La retribuzione totale di Carl ($USD 1.30M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Carl è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Carl Spana (62 yo)

24.2yrs

Mandato

US$1,303,800

Compensazione

Dr. Carl Spana, Ph D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Carl Spana	Co-Founder	24.2yrs	US$1.30m	1.35% $ 384.3k
Stephen Wills	CFO, COO	26.8yrs	US$1.19m	1.22% $ 346.1k
Burns McClellan	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Stephen Slusher	Chief Legal Officer	no data	Nessun dato	Nessun dato
Michael Raizman	Chief Medical Officer	3.2yrs	Nessun dato	Nessun dato
James Hattersley	Senior Vice President of Business Development	3.2yrs	Nessun dato	Nessun dato
John Dodd	Senior Vice President of Preclinical Development	no data	Nessun dato	Nessun dato
Robert Jordan	Senior Vice President of Program Operations	no data	Nessun dato	Nessun dato

13.7yrs

Durata media

64yo

Età media

Gestione esperta: Il team dirigenziale di PTN è esperto e expertise (durata media dell'incarico 13.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Carl Spana	Co-Founder	28.2yrs	US$1.30m	1.35% $ 384.3k
John K. Prendergast	Independent Non-Executive Chairman	28yrs	US$154.88k	0.33% $ 93.1k
Arlene Morris	Independent Director	9.2yrs	US$97.47k	0.21% $ 61.1k
Robert deVeer	Independent Director	25.8yrs	US$112.47k	0.20% $ 56.0k
Alan Dunton	Independent Director	13.2yrs	US$112.47k	0.22% $ 62.2k
Anthony Manning	Independent Director	6.9yrs	US$97.47k	0.19% $ 53.0k
Raymond Rosen	Member of Female Sexual Dysfunction Expert Panel	no data	Nessun dato	Nessun dato
Michael Perelman	Member of Female Sexual Dysfunction Expert Panel	19.3yrs	Nessun dato	Nessun dato
J. Hull	Independent Director	18.9yrs	US$102.47k	0.22% $ 62.1k
Anita Clayton	Member of Female Sexual Dysfunction Expert Panel	no data	Nessun dato	Nessun dato
Leonard Derogatis	Member of Female Sexual Dysfunction Expert Panel	no data	Nessun dato	Nessun dato
Stanley Althof	Member of Female Sexual Dysfunction Expert Panel	no data	Nessun dato	Nessun dato

19.1yrs

Durata media

70yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PTN è composto da personale esperto e esperto (durata media dell'incarico 19.1 anni).

Palatin Technologies Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Insufficient new directors

Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022

Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022

Insufficient new directors

Recent updates

New major risk - Shareholder dilution

Forecast to breakeven in 2027

Palatin Technologies, Inc. Announces Initiation of Phase 2 Clinical Study of Bremelanotide Co-Administered with PDE5i for Treatment of Erectile Dysfunction

Palatin Technologies, Inc. Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024

Third quarter 2024 earnings released: US$0.53 loss per share (vs US$0.63 loss in 3Q 2023)

Consensus EPS estimates fall by 39%

Palatin Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (Ded) Clinical Data Results Presented At American Society of Cataract and Refractive Surgery (Ascrs) 2024

Price target decreased by 73% to US$11.50

Consensus revenue estimates fall by 65%

Consensus revenue estimates fall by 65%

No longer forecast to breakeven

Price target increased by 40% to US$60.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

New major risk - Shareholder dilution

Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $10.000006 million.

New major risk - Share price stability

Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024

Forecast to breakeven in 2026

Consensus EPS estimates fall by 12%

Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.29 loss

Palatin Technologies, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding

New major risk - Share price stability

Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Consensus revenue estimates increase by 28%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Palatin Technologies, Inc. to Report Q4, 2023 Results on Sep 28, 2023

Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease

Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

New minor risk - Share price stability

Consensus revenue estimates fall by 24%

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Palatin Technologies, Inc. to Report Q3, 2023 Results on May 16, 2023

Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Consensus revenue estimates decrease by 42%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Palatin Technologies, Inc. to Report Q2, 2023 Results on Feb 15, 2023

Palatin Technologies Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

Consensus revenue estimates increase by 72%

Price target decreased to US$43.00

Insufficient new directors

Palatin Technologies, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $9.999921 million.

Palatin Technologies, Inc. Announces First Patient Has Been Enrolled in the Pl8177-205 Study with Palatin's Pl8177

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Palatin Technologies, Inc. to Report Q4, 2022 Results on Sep 22, 2022

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022

Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Palatin Technologies, Inc. to Report Q3, 2022 Results on May 17, 2022

Price target increased to US$3.33

Insufficient new directors

Consensus forecasts updated

Consensus forecasts updated